STOCK TITAN

Boundless Bio (BOLD): Citadel entities and Ken Griffin report 0.6% ownership

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Boundless Bio, Inc. received an amended Schedule 13G filing from a group of Citadel-related entities and Kenneth Griffin regarding their holdings of common stock. Based on 22,474,777 Shares outstanding as of June 15, 2026, Citadel Securities LLC may be deemed to beneficially own 65,617 Shares, while each of Citadel Securities Group LP, Citadel Securities GP LLC and Mr. Griffin may be deemed to beneficially own 145,118 Shares, or 0.6% of the outstanding Shares. The filing confirms that the Reporting Persons collectively report ownership of 5 percent or less of this class, with only shared, and no sole, voting or dispositive power over these Shares.

Positive

  • None.

Negative

  • None.
Shares outstanding 22,474,777 Shares Shares outstanding as of June 15, 2026 used for ownership percentages
Citadel Securities LLC holdings 65,617 Shares Beneficially owned by Citadel Securities LLC, representing 0.3% of class
Griffin reported holdings 145,118 Shares Shares Kenneth Griffin may be deemed to beneficially own, 0.6% of class
Citadel Securities Group LP holdings 145,118 Shares Beneficially owned by Citadel Securities Group LP, 0.6% of outstanding Shares
Ownership threshold 5 percent or less Filing states ownership of 5 percent or less of the class
beneficially own financial
"may be deemed to beneficially own 145,118 Shares"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
shared voting power financial
"Shared Voting Power 145,118.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power financial
"Shared Dispositive Power 145,118.00"
Schedule 13G/A regulatory
"Ownership of 5 Percent or Less of a Class."
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
attorney-in-fact regulatory
"Seth Levy, attorney-in-fact*"
An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

What stake in Boundless Bio (BOLD) is reported by Citadel Securities LLC?

Citadel Securities LLC may be deemed to beneficially own 65,617 Shares of Boundless Bio common stock, representing 0.3% of the Shares outstanding based on 22,474,777 Shares outstanding as of June 15, 2026.

How many Boundless Bio (BOLD) shares may Kenneth Griffin be deemed to own?

Kenneth Griffin may be deemed to beneficially own 145,118 Shares of Boundless Bio common stock, which the filing states constitutes 0.6% of the Shares outstanding, using the issuer’s 22,474,777 outstanding Shares figure.

Do the Citadel reporting persons own more than 5% of Boundless Bio (BOLD)?

No. The Schedule 13G/A explicitly states that the Reporting Persons’ holdings constitute 5 percent or less of Boundless Bio’s common stock class, keeping them below the 5% beneficial ownership threshold.

What is the total number of Boundless Bio (BOLD) shares outstanding used in this 13G/A?

The percent-of-class calculations are based on 22,474,777 Shares outstanding as of June 15, 2026, which Boundless Bio reported in a prospectus dated June 23, 2026 and cited by the Reporting Persons.

Do the Citadel entities report sole or shared voting power over Boundless Bio (BOLD) shares?

The filing shows no sole voting power for any Reporting Person. Citadel Securities LLC has 65,617 Shares with shared voting power, and Citadel Securities Group LP, Citadel Securities GP LLC and Kenneth Griffin each report shared voting power over 145,118 Shares.

Who signed the Schedule 13G/A for the Citadel reporting persons in Boundless Bio (BOLD)?

Seth Levy signed as Authorized Signatory for the Citadel entities and as attorney-in-fact for Kenneth Griffin, pursuant to a previously filed power of attorney incorporated by reference.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





10170A100

(CUSIP Number)
06/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: The percentages reported in this Schedule 13G are based upon 22,474,777 Shares outstanding as of June 15, 2026 (according to the issuer's prospectus as filed with the Securities and Exchange Commission on June 23, 2026).


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Citadel Advisors LLC
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:08/14/2026
Citadel Advisors Holdings LP
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:08/14/2026
Citadel GP LLC
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:08/14/2026
Citadel Securities LLC
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:08/14/2026
Citadel Securities Group LP
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:08/14/2026
Citadel Securities GP LLC
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:08/14/2026
Kenneth Griffin
Signature:/s/ Seth Levy
Name/Title:Seth Levy, attorney-in-fact*
Date:08/14/2026

Comments accompanying signature: * Seth Levy is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein. The power of attorney was filed as an attachment to a filing by Citadel Advisors LLC on Schedule 13G for Allakos Inc. on October 13, 2023.